• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The CRAFITY score: A promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations.

作者信息

Yang Yi, Ouyang Jingzhong, Zhou Yanzhao, Zhou Jinxue, Zhao Hong

机构信息

Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Key Laboratory of Gene Editing Screening and Research and Development (R&D) of Digestive System Tumor Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Department of Hepatobiliary and Pancreatic Surgery, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.

出版信息

J Hepatol. 2022 Aug;77(2):574-576. doi: 10.1016/j.jhep.2022.03.018. Epub 2022 Mar 26.

DOI:10.1016/j.jhep.2022.03.018
PMID:35351522
Abstract
摘要

相似文献

1
The CRAFITY score: A promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations.CRAFITY评分：酪氨酸激酶抑制剂与免疫疗法联合治疗肝细胞癌患者的一种有前景的预后预测指标。
J Hepatol. 2022 Aug;77(2):574-576. doi: 10.1016/j.jhep.2022.03.018. Epub 2022 Mar 26.
2
Reply to: "The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations".回复：“CRAFITY评分：酪氨酸激酶抑制剂与免疫疗法联合治疗肝细胞癌患者的一种有前景的预后预测指标”
J Hepatol. 2022 Aug;77(2):576-577. doi: 10.1016/j.jhep.2022.04.030. Epub 2022 May 5.
3
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.免疫治疗肝细胞癌患者的预后——CRAFITY 评分的建立和验证。
J Hepatol. 2022 Feb;76(2):353-363. doi: 10.1016/j.jhep.2021.09.035. Epub 2021 Oct 12.
4
Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis.CRAFITY 评分对接受免疫治疗的肝细胞癌的预后意义：系统评价和荟萃分析。
BMC Cancer. 2023 Mar 13;23(1):236. doi: 10.1186/s12885-023-10686-9.
5
The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy.CRAFITY评分：接受免疫治疗的肝细胞癌患者预后预测的新指标。
J Hepatol. 2022 May;76(5):1232-1233. doi: 10.1016/j.jhep.2021.12.033. Epub 2022 Jan 19.
6
Reply to: "The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy".回复：“CRAFITY评分：接受免疫治疗的肝细胞癌患者预后预测的新指南”。
J Hepatol. 2022 May;76(5):1233-1234. doi: 10.1016/j.jhep.2022.02.002. Epub 2022 Feb 14.
7
Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?CRAFITY 评分是否能更好地预测接受局部免疫治疗的肝细胞癌患者的预后和不良事件？
Hepatol Int. 2023 Oct;17(5):1279-1288. doi: 10.1007/s12072-023-10535-8. Epub 2023 May 2.
8
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.在接受阿替利珠单抗联合贝伐珠单抗治疗的肝细胞癌患者中，C 反应蛋白和甲胎蛋白对免疫治疗评分的预后影响：一项多中心回顾性研究。
Hepatol Int. 2022 Oct;16(5):1150-1160. doi: 10.1007/s12072-022-10358-z. Epub 2022 Jun 24.
9
The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapy.MAPS-CRAFITY 评分：一种新的预测工具，可预测不可切除的肝细胞癌接受靶向治疗联合免疫治疗的疗效。
Hepatol Int. 2023 Dec;17(6):1519-1531. doi: 10.1007/s12072-023-10580-3. Epub 2023 Sep 14.
10
The GRAPHS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with immunotherapy.GRAPHS-CRAFITY 评分：一种新型疗效预测工具，用于治疗不可切除的肝细胞癌的免疫治疗。
Radiol Med. 2024 Feb;129(2):188-201. doi: 10.1007/s11547-023-01753-z. Epub 2024 Jan 5.

引用本文的文献

1
CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma.CRAFITY评分和列线图预测乐伐替尼联合免疫检查点抑制剂治疗肝细胞癌的临床疗效。
World J Gastroenterol. 2025 Feb 21;31(7):101672. doi: 10.3748/wjg.v31.i7.101672.
2
The CRAFITY score emerges as a paramount prognostic indicator in hepatocellular carcinoma patients received Lenvatinib and Pembrolizumab.CRAFITY 评分在接受仑伐替尼和帕博利珠单抗治疗的肝细胞癌患者中是一个重要的预后指标。
Front Immunol. 2024 Nov 1;15:1474456. doi: 10.3389/fimmu.2024.1474456. eCollection 2024.
3
Prognostic Prediction and Risk Stratification of Transarterial Chemoembolization Combined with Targeted Therapy and Immunotherapy for Unresectable Hepatocellular Carcinoma: A Dual-Center Study.
经动脉化疗栓塞联合靶向治疗和免疫治疗对不可切除肝细胞癌的预后预测及风险分层：一项双中心研究
J Hepatocell Carcinoma. 2024 Nov 7;11:2169-2179. doi: 10.2147/JHC.S487080. eCollection 2024.
4
Circulating Biomarkers Predict Immunotherapeutic Response in Hepatocellular Carcinoma Using a Machine Learning Method.使用机器学习方法，循环生物标志物可预测肝细胞癌的免疫治疗反应。
J Hepatocell Carcinoma. 2024 Oct 30;11:2133-2144. doi: 10.2147/JHC.S474593. eCollection 2024.
5
Efficacy and safety of regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study.瑞戈非尼作为一线单药或联合免疫检查点抑制剂治疗晚期肝细胞癌的疗效和安全性：一项回顾性队列研究
J Gastrointest Oncol. 2024 Jun 30;15(3):1072-1081. doi: 10.21037/jgo-24-315. Epub 2024 Jun 27.
6
Alpha-fetoprotein: Past, present, and future.甲胎蛋白：过去、现在与未来。
Hepatol Commun. 2024 Apr 12;8(5). doi: 10.1097/HC9.0000000000000422. eCollection 2024 May 1.
7
The prognostic and antitumor roles of key genes of ferroptosis in liver hepatocellular cancer and stomach adenocarcinoma.铁死亡关键基因在肝细胞肝癌和胃腺癌中的预后和抗肿瘤作用。
Cancer Biomark. 2024;39(4):335-347. doi: 10.3233/CBM-230114.
8
Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.经动脉化疗栓塞联合酪氨酸激酶抑制剂和 PD-1 抑制剂治疗晚期肝细胞癌的 CRAFITY 评分的实用性和预测价值。
BMC Cancer. 2024 Feb 16;24(1):223. doi: 10.1186/s12885-024-11936-0.
9
Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma.晚期肝细胞癌患者基于PD-1/PD-L1抑制剂治疗的生物标志物和预后因素
Biomark Res. 2024 Feb 14;12(1):26. doi: 10.1186/s40364-023-00535-z.
10
Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma.预测免疫检查点抑制剂在肝细胞癌中的疗效的生物标志物。
Front Immunol. 2023 Dec 22;14:1326097. doi: 10.3389/fimmu.2023.1326097. eCollection 2023.